Meningococcal vaccine groups A C W135 and Y polysaccharide - Pfizer

Drug Profile

Meningococcal vaccine groups A C W135 and Y polysaccharide - Pfizer

Alternative Names: ACWY Vax; Mencevax ACWY

Latest Information Update: 06 Oct 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 01 Oct 2015 Pfizer acquires meningococcal vaccine groups A, C, W135 and Y polysaccharide from GlaxoSmithKline
  • 22 Jun 2015 Registered for Meningococcal infections (In adolescents, In adults, In children, Prevention) in Middle East, Latin America, Europe, Australia, Africa, Asia (SC) before June 2015
  • 22 Jun 2015 Pfizer enters into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, including Mencevax vaccine ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top